NGS Oncology Market Report 2026

NGS Oncology Market Overview

• NGS Oncology market size has reached to $19.33 billion in 2025 • Expected to grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Increasing Cancer Prevalence Fueling The Growth Of The Market Due To Rising Demand For Precision Diagnostics • Market Trend: Next-Generation Sequencing Technologies Transforming Oncology Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under NGS Oncology Market?

Next-generation sequencing (NGS) oncology refers to the use of advanced sequencing technologies to analyze the genetic makeup of cancer cells. It allows for the identification of specific mutations, genetic alterations, and biomarkers that can help guide personalized treatment plans, predict treatment responses, and improve the overall management of cancer patients. NGS oncology enables precision medicine, where therapies are tailored based on the genetic profile of the tumor. The main sequencing technologies in NGS oncology include targeted sequencing, genomics, transcriptomics, and epigenomics. Targeted sequencing is a genomic technique that focuses on sequencing specific genes or regions of interest within the genome to identify genetic variations relevant to diseases or traits. These technologies are offered in the form of platforms, kits, and services. The workflow involves stages such as pre-sequencing, sequencing, and data analysis. They are used for various applications, including genetic screening, hereditary genetic testing, hematological malignancies, solid tumors, and others, catering to end users including hospitals and clinics, clinical research organizations (CROs), academic and research institutes, pharmaceutical and biotechnology companies, and others.

What Is The NGS Oncology Market Growth Forecast?

The ngs oncology market size is expected to see rapid growth in the next few years. It will grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to expansion of precision oncology programs, growing demand for personalized cancer treatment, increasing approvals of ngs-based diagnostics, advancements in bioinformatics analytics, integration of ngs into clinical guidelines. Major trends in the forecast period include expansion of comprehensive tumor profiling, rising adoption of liquid biopsy NGS, increasing clinical utility of multi-gene panels, integration of NGS in routine oncology diagnostics, growing demand for faster turnaround sequencing workflows.

What Is The Driver Of The NGS Oncology Market?

The rising prevalence of cancer is expected to propel the growth of the NGS oncology market going forward. Cancer is a disease in which abnormal cells grow uncontrollably and can invade other parts of the body, disrupting normal physiological functions. The rise in cancer prevalence is primarily driven by aging populations, population growth, and increasing exposure to risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology supports public health and patient care by enabling early detection, precise diagnosis, and personalized treatment through detailed genetic profiling of tumors. For instance, in January 2024, according to the data published by the American Cancer Society, a US-based non-profit organization, the United States is projected to see 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, compared to 1,958,310 cases and 609,820 deaths in 2023. Therefore, the rising prevalence of cancer is driving the growth of the NGS oncology industry.

Key Players In The Global NGS Oncology Market

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Global NGS Oncology Market Trends and Insights

Major companies operating in the NGS oncology market are focusing on developing innovative solutions such as liquid biopsy research assays to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids, such as blood, to detect genetic mutations or other molecular markers associated with cancer, allowing for non-invasive cancer detection and monitoring. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing (NGS) technology, expanded its oncology portfolio for NovaSeq X Series users. The company now offers the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays enable laboratories to broaden oncology research capabilities for both tissue and liquid biopsy samples, featuring improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.

What Are Latest Mergers And Acquisitions In The NGS Oncology Market?

In December 2024, Deerfield Management Company, a US-based investment firm, acquired Singular Genomics for an undisclosed amount. With this acquisition, Deerfield Management Company aims to enhance its portfolio by integrating Singular Genomics' next-generation sequencing and spatial multiomics technologies, advancing research and clinical applications. Singular Genomics is a US-based biotechnology company specializing in next-generation sequencing and multiomics technologies.

What Defines the NGS Oncology Market?

The NGS oncology market consists of revenues earned by entities by providing services such as companion diagnostics, liquid biopsy analysis, genetic mutation analysis, bioinformatics, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The NGS oncology market also includes sales of target enrichment kits, library preparation kits, data analysis pipelines, bioinformatics software, and tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the NGS Oncology Market Report 2026?

The ngs oncology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ngs oncology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.